Business Context and Reporting Period
This Form 8-K filing by Recursion Pharmaceuticals, Inc. (RXRX) reports a significant corporate event dated December 2, 2021. The company, incorporated in Delaware and listed on the Nasdaq Global Select Market, is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than periodic financial performance.
Material Changes
On December 2, 2021, Recursion Pharmaceuticals entered into a Collaboration Expansion Agreement with Bayer AG. This agreement amends the Research Collaboration and Option Agreement originally dated August 28, 2020. A press release detailing this expansion was issued on December 6, 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the collaboration amendment. The primary disclosure is the execution of the Expansion Agreement.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific terms of the Bayer AG Collaboration Expansion Agreement.
- Verify the financial impact of the amendment, as this 8-K does not quantify potential payments or milestones.
- Confirm the status of the original August 28, 2020, agreement to understand the scope of the expansion.